Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Vaccination site erythema, Vaccination site induration, Vaccination site inflammation, Vaccination site mass
Clinical narrative: Big bump (1.25"x1/2") on the Injection Site after booster; Hot to the touch Injection Site  (97.9 F) after booster; Hard bump (1.25"x1/2") on the Injection Site after booster; Red on the Injection Site after booster/Redness spreading; Inflamed Injection Site after booster/Throbbing Injection Site after booster; Itching Injection Site after booster; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Big bump (1.25"x1/2") on the Injection Site after booster), VACCINATION SITE WARMTH (Hot to the touch Injection Site  (97.9 F) after booster), VACCINATION SITE INDURATION (Hard bump (1.25"x1/2") on the Injection Site after booster), VACCINATION SITE ERYTHEMA (Red on the Injection Site after booster/Redness spreading) and VACCINATION SITE INFLAMMATION (Inflamed Injection Site after booster/Throbbing Injection Site after booster) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039F21A, 027A21A and 019B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history report information was reported.  Concomitant products included INFLUENZA VACCINE INACT SPLIT 4V (FLUZONE QUADRIVALENT) from 29-Sep-2021 to an unknown date for an unknown indication.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Oct-2021, the patient experienced VACCINATION SITE MASS (Big bump (1.25"x1/2") on the Injection Site after booster), VACCINATION SITE WARMTH (Hot to the touch Injection Site  (97.9 F) after booster), VACCINATION SITE INDURATION (Hard bump (1.25"x1/2") on the Injection Site after booster), VACCINATION SITE ERYTHEMA (Red on the Injection Site after booster/Redness spreading), VACCINATION SITE INFLAMMATION (Inflamed Injection Site after booster/Throbbing Injection Site after booster) and VACCINATION SITE PRURITUS (Itching Injection Site after booster). At the time of the report, VACCINATION SITE MASS (Big bump (1.25"x1/2") on the Injection Site after booster), VACCINATION SITE WARMTH (Hot to the touch Injection Site  (97.9 F) after booster), VACCINATION SITE INDURATION (Hard bump (1.25"x1/2") on the Injection Site after booster), VACCINATION SITE ERYTHEMA (Red on the Injection Site after booster/Redness spreading), VACCINATION SITE INFLAMMATION (Inflamed Injection Site after booster/Throbbing Injection Site after booster) and VACCINATION SITE PRURITUS (Itching Injection Site after booster) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 97.9 fahrenheit (normal) 97.9 Fahrenheit.         Treatment medications was not reported.